1. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer
- Author
-
Juho Jasu, Teemu Tolonen, Emmanuel S. Antonarakis, Himisha Beltran, Susan Halabi, Mario A. Eisenberger, Michael A. Carducci, Yohann Loriot, Kim Van der Eecken, M.P.J.K. (Martijn) Lolkema, Charles J. Ryan, Sinja Taavitsainen, Silke Gillessen, Gunilla Högnäs, Timo Talvitie, Robert J. Taylor, Antti Koskenalho, Piet Ost, Teemu J. Murtola, Irina Rinta-Kiikka, Teuvo Tammela, A Auvinen, Paula Kujala, Thomas J. Smith, Pirkko Liisa Kellokumpu-Lehtinen, William B. Isaacs, Matti Nykter, Juha Kesseli, G. Steven Bova, Juho Jasu, Teemu Tolonen, Emmanuel S. Antonarakis, Himisha Beltran, Susan Halabi, Mario A. Eisenberger, Michael A. Carducci, Yohann Loriot, Kim Van der Eecken, M.P.J.K. (Martijn) Lolkema, Charles J. Ryan, Sinja Taavitsainen, Silke Gillessen, Gunilla Högnäs, Timo Talvitie, Robert J. Taylor, Antti Koskenalho, Piet Ost, Teemu J. Murtola, Irina Rinta-Kiikka, Teuvo Tammela, A Auvinen, Paula Kujala, Thomas J. Smith, Pirkko Liisa Kellokumpu-Lehtinen, William B. Isaacs, Matti Nykter, Juha Kesseli, and G. Steven Bova
- Abstract
Background: Systematic identification of data essential for outcome prediction in metastatic prostate cancer (mPC) would accelerate development of precision oncology. Objective: To identify novel phenotypes and features associated with mPC outcome, and to identify biomarker and data requirements to be tested in future precision oncology trials. Design, setting, and participants: We analyzed deep longitudinal clinical, neuroendocrine expression, and autopsy data of 33 men who died from mPC between 1995 and 20
- Published
- 2021
- Full Text
- View/download PDF